Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2

European Cytokine Network

Volumn 11, Issue 3, 2000, Pages 391-396

  Locker, G J ^a   Kofler, J ^a   Stoiser, B ^a   Wilfing, A ^a   Wenzel, C ^a   Wogerbauer M ^a   Steger, G G ^a   Zielinski, C C ^a   Mader, R ^a   Burgmann, H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti inflammatory cytokines; Immunotherapy; Interleukin 2; Nitrate; Nitric oxide; Pro inflammatory cytokines

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HYPOTENSION; IMMUNOMODULATION; LIVER CELL CARCINOMA; MALE; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PATHOPHYSIOLOGY; REVIEW; SOFT TISSUE SARCOMA;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INFUSIONS, INTRAVENOUS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; MALE; MIDDLE AGED; NEOPLASMS; NITRATES; NITRIC OXIDE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT PROTEINS;

EID: 0034456552     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Principles and application of biologic therapy
2. The immunotherapy and gene therapy of cancer
3. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment related morbidity and histologic findings
4. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2
5. Clinical toxicity of interleukin-2
6. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders
7. Mechanisms of interleukin-2-induced hepatic toxicity
8. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells
9. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock
10. Evidence of increased nitric oxide production in patients with the sepsis syndrome
11. Nitric oxide in sepsis and endotoxaemia
12. The L-arginine-nitric oxide pathway
13. Nitric oxide: Biological mediator, modulator and effector
14. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice
15. Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin-2
16. The role of active inducible nitric oxide synthase expression in the pathogenesis of capillary leak syndrome resulting from interleukin-2 therapy in mice
17. Relation between pro- and anti-inflammatory cytokines and the production of nitric oxide (NO) in severe sepsis
18. The molecule of the year
19. NO news is good news
20. Roles of nitric oxide in surgical infection and sepsis
21. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
22. Evidence for increased nitric oxide production after liver transplantation in humans
23. The role of nitric oxide in interleukin-2 therapy induced hypotension
24. Rapid cytokine release in cancer patients treated with interleukin-2
25. NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2 induced hypotension
26. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice
27. Effect on nitric synthase inhibitors on hypotension in patients with septic shock
28. Effects of a nitric oxide synthase inhibitor in humans with septic shock
29. Fatal cardiac side effects of L-NMMA?
30. Sepsis research: We must change course
31. Just say no to NO, yes?
32. Endothelin-1 inhibits the expression of inducible nitric oxide synthase
33. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells
34. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia
35. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats
36. Differential effects of endogenous and exogenous nitric oxide on the release of endothelin-1 from the intact perfused rat adrenal gland in situ
37. Nitric oxide-endothelin-1 interaction in humans
38. Endothelin-1 enhances nitric oxide-induced cytotoxicity in vascular smooth muscle
39. In vivo cytokine production and recombinant interleukin-2 immunotherapy: An insight into the possible mechanisms underlying clinical responses
40. Nitric oxide synthesis contributes to IL-2 induced antitumor responses against intraperitoneal Meth A tumor
41. Nitric oxide attenuates interleukin-2 induced lung injury
42. Inhibition of nitric oxide synthesis does not improve interleukin-2 mediated antitumor effects in vivo
43. Effects of N(G)-Nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, on IL-2-induced LAK cell generation in vivo and in vitro in healthy and tumor-bearing mice